While many companies and institutions are setting about mapping protein-protein interactions, Glycominds Inc. is taking a different tack in the post-genomic era. The company is developing technologies that map interactions between proteins and complex carbohydrates, or glycans. Glycominds maintains that its carbohydrate chip will make feasible research in this area, which has been hampered by a lack of high throughput technologies.

Glycans affect multiple aspects of a protein's functionality, including folding, cellular localization, circulation half-life and immune response. Thus Glycominds aims to use its Glycomics database and GlycoChip technology to provide partners with drug development services that include target evaluation and toxicity screening.